|
1
|
Detterbeck FC, Falen S, Rivera MP, Halle
JS, Socinski MA, et al: Seeking a home for a PET, part 2: Defining
the appropriate place for positron emission tomography imaging in
the staging of patients with suspected lung cancer. Chest.
125:2300–2308. 2004. View Article : Google Scholar
|
|
2
|
Silvestri GA, Tanoue LT, Margolis ML,
Barker J and Detterbeck F: The noninvasive staging of non-small
cell lung cancer: the guidelines. Chest. 123:S147–S156. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Spaggiari L, Sverzellati N, Versari A,
Paci M, Ferrari G, Nicoli F, et al: Evaluation of N parameter in
the staging of non-small cell lung cancer: role of CT and PET.
Radiol Med. 109:449–459. 2005.PubMed/NCBI
|
|
4
|
Aeker MR and Burrell SC: Utility of
18F-FDG PET in evaluating cancers of lung. J Nucl Med
Technol. 33:69–74. 2005.
|
|
5
|
Shiraki N, Hara M, Ogino H, Shibamoto Y,
Iida A, Tamaki T, Murase T and Eimoto T: False-positive and
true-negative hilar and mediastinal lymph nodes on FDG-PET -
radiological-pathological correlation. Ann Nucl Med. 18:23–28.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hara T, Kosaka N, Suzuki T, Kudo K and
Niino H: Uptake rates of 18F-fluorodeoxyglucose and
11C-choline in lung cancer and pulmonary tuberculosis: a
positron emission tomography study. Chest. 124:893–901. 2003.
|
|
7
|
Tian M, Zhang H, Oriuchi N, et al:
Comparison of 11C-choline PET and FDG PET for the
differential diagnosis of malignant tumors. Eur J Nucl Med Mol
Imaging. 31:1064–1072. 2004.
|
|
8
|
Konishi J, Yamazaki K, Tsukamoto E, Tamaki
N, Onodera Y, Otake T, Morikawa T, Kinoshita I, Dosaka-Akita H and
Nishimura M: Mediastinal lymph node staging by FDG-PET in patients
with non-small cell lung cancer: analysis of false-positive FDG-PET
findings. Respiration. 70:500–506. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hara T, Inagaki K, Kosaka N and Morita T:
Sensitive detection of mediastinal lymph node metastasis of lung
cancer with 11C-choline PET. J Nucl Med. 41:1507–1513.
2000.PubMed/NCBI
|
|
10
|
Roivainen A, Forsback S, Gronroos T, et
al: Blood metabolism of [methyl-11C]choline;
implications for in vivo imaging with positron emission tomography.
Eur J Nucl Med. 27:25–32. 2000.
|
|
11
|
Golfman LS, Bakovic M and Vance E:
Transcription of the CTP: phosphocholine cytidylyltransferase alpha
gene is enhanced during the S phase of the cell cycle. J Biol Chem.
276:43688–43692. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Janardhan S, Srivani P and Sastry GN:
Choline kinase: an important target for cancer. Curr Med Chem.
13:1169–1186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Agassandian M, Zhou J, Tephly LA, et al:
Oxysterols inhibit phosphatidylcholine synthesis via ERKdocking and
phosphorylation of CTP:phosphocholine cytidylyltransferase. J Biol
Chem. 280:21577–21587. 2005. View Article : Google Scholar
|
|
14
|
Martin B, Paesmans M, Mascaux C, et al:
Ki-67 expression and patients survival in lung cancer: systematic
review of the literature with meta-analysis. Br J Cancer.
91:2018–2025. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakamura H, Hirata T, Kitamura H and
Nishikawa J: Correlation of the standardized uptake value in
FDG-PET with the expression level of cell-cycle-related molecular
biomarkers in resected non-small cell lung cancers. Ann Thorac
Cardiovasc Surg. 15:304–310. 2009.PubMed/NCBI
|
|
16
|
Yamamoto Y, Nishiyama Y, Ishikawa S,
Nakano J, Chang SS, Bandoh S, Kanaji N, Haba R, Kushida Y and
Ohkawa M: Correlation of 18F-FLT and 18F-FDG
uptake on PET with Ki-67 immunohistochemistry in non-small cell
lung cancer. Eur J Nucl Med Mol Imaging. 34:1610–1616. 2007.
|
|
17
|
Takenaka T, Yano T, Ito K, Morodomi Y,
Miura N, Kawano D, Shoji F, Abe K, Honda H and Maehara Y:
Biological significance of the maximum standardized uptake values
on positron emission tomography in non-small cell lung cancer. J
Surg Oncol. 100:688–692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han B, Lin S, Yu LJ, Wang RZ and Wang YY:
Correlation of 18F-FDG PET activity with expressions of
survivin, Ki67, and CD34 in non-small-cell lung cancer. Nucl Med
Commun. 30:214–219. 2009.
|
|
19
|
Nguyen XC, Lee WW, Chung JH, Park SY, Sung
SW, Kim YK, So Y, Lee DS, Chung JK, Lee MC and Kim SE: FDG uptake,
glucose transporter type 1, and Ki-67 expressions in non-small-cell
lung cancer: correlations and prognostic values. Eur J Radiol.
62:214–219. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vesselle H, Salskov A, Turcotte E, Wiens
L, Schmidt R, Jordan CD, Vallières E and Wood DE: Relationship
between non-small cell lung cancer FDG uptake at PET, tumor
histology, and Ki-67 proliferation index. J Thorac Oncol.
3:971–978. 2008. View Article : Google Scholar : PubMed/NCBI
|
